產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-SAMHD1/MOP5抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-SAMHD1/MOP5抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-SAMHD1/MOP5
Cat. Number:
Anti-SAMHD1/MOP5抗體KL-8060R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Putative nuclease involved in innate immune response by acting as a negative regulator of the cell-intrinsic antiviral response. Anti-SAMHD1/MOP5抗體May play a role in mediating proinflammatory responses to TNF-alpha signaling.
Tissue specificity: Expressed in heart, skeletal muscle, spleen, liver, small intestine, placenta, lung and peripheral blood leukocytes. No expression is seen in brain and thymus.
Involvement in disease:
Defects in SAMHD1 are the cause of Aicardi-Goutieres syndrome type 5 (AGS5) . A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.
Tissue specificity: Expressed in heart, skeletal muscle, spleen, liver, small intestine, placenta, lung and peripheral blood leukocytes. No expression is seen in brain and thymus.
Involvement in disease:
Defects in SAMHD1 are the cause of Aicardi-Goutieres syndrome type 5 (AGS5) . A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.
Also known as:
DCIP; Dendritic cell derived IFNG induced protein; Anti-SAMHD1/MOP5抗體Dendritic cell-derived IFNG-induced protein; HD domain containing 1; HDDC1; Mg11; Monocyte protein 5; MOP 5; MOP5; OTTHUMP00000030889; SAM domain and HD domain 1; SAM domain and HD domain containing protein 1; SAM domain and HD domain-containing protein 1; SAMH1_HUMAN; Samhd1; SBBI88.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Cow, Horse, Zebrafish, Sheep, .
●
Immunogen: KLH conjugated synthetic peptideAnti-SAMHD1/MOP5抗體 derived from human SAMHD1/HDDC1/MOP5.
●
Predicted Molecular Weight: 72kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-SAMHD1/MOP5抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-SAMHD1/MOP5抗體
Optimal working dilutions must be determined by the end user.
